TCW Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.87M Buy
4,191
+203
+5% +$94.7K 0.01% 289
2025
Q4
$1.81M Buy
+3,988
New +$1.72M 0.01% 286
2021
Q2
Sell
-11,981
Closed -$2.58M 362
2021
Q1
$2.58M Buy
11,981
+6
+0.1% +$1.32K 0.02% 241
2020
Q4
$2.83M Buy
+11,975
New +$2.75M 0.02% 226
2017
Q1
Sell
-25,035
Closed -$1.84M 615
2016
Q4
$1.84M Hold
25,035
0.01% 370
2016
Q3
$2.18M Sell
25,035
-1,608
-6% -$152K 0.02% 312
2016
Q2
$2.29M Buy
26,643
+750
+3% +$64.8K 0.02% 299
2016
Q1
$2.06M Sell
25,893
-320
-1% -$28.9K 0.02% 331
2015
Q4
$3.3M Buy
26,213
+670
+3% +$80.9K 0.02% 259
2015
Q3
$2.66M Sell
25,543
-2,250
-8% -$289K 0.02% 292
2015
Q2
$3.43M Sell
27,793
-51,711
-65% -$6.52M 0.02% 294
2015
Q1
$9.38M Buy
79,504
+2,361
+3% +$283K 0.05% 261
2014
Q4
$9.16M Sell
77,143
-48,350
-39% -$5.45M 0.04% 279
2014
Q3
$14.1M Sell
125,493
-1,750
-1% -$167K 0.06% 259
2014
Q2
$12M Buy
127,243
+3,900
+3% +$273K 0.05% 301
2014
Q1
$8.72M Sell
123,343
-4,800
-4% -$380K 0.04% 359
2013
Q4
$9.52M Buy
128,143
+245
+0.2% +$17.1K 0.04% 340
2013
Q3
$9.7M Buy
127,898
+114,925
+886% +$9.15M 0.04% 316
2013
Q2
$1.04M Buy
+12,973
New +$955K 0.01% 677

Other funds holding VRTX

TCW Group's VRTX Position: Q1 2026 in Review

TCW Group increased its Vertex Pharmaceuticals (VRTX) stake by 5.1% in Q1 2026, buying an estimated $94.7K and bringing the position to 4,191 shares worth $1.87M. The position accounts for 0.01% of the portfolio, ranked #289.

TCW Group first reported a position in VRTX in Q2 2013 and has held it in 19 quarters since. The position peaked at $14.1M in Q3 2014. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • TCW Group held 4,191 shares of Vertex Pharmaceuticals worth $1.87M as of Q1 2026.
  • TCW Group bought 203 Vertex Pharmaceuticals shares in Q1 2026, an estimated $94.7K.
  • Vertex Pharmaceuticals made up 0.01% of TCW Group's portfolio in Q1 2026, its #289 holding.
  • TCW Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 19 quarters since.
  • TCW Group's Vertex Pharmaceuticals position peaked at $14.1M in Q3 2014.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on TCW Group's 13F filing for Q1 2026, filed 14 May 2026.